IMR Press / FBL / Volume 11 / Issue 3 / DOI: 10.2741/2005

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Uridine phosphorylase in breast cancer: a new prognostic factor?
Show Less
1 Department of Medical Microbiology, Immunology, and Cell Biology, Cancer Institute, Southern Illinois University School of Medicine, 911 North Rutledge Street, Springfield, IL 62702
2 Department of Internal Medicine, Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520
3 Division of Drug Development, Nevada Cancer Institute, 10441 West Twain Boulevard, Las Vegas, NV 89117
Academic Editor:Kounosuke Watabe
Front. Biosci. (Landmark Ed) 2006, 11(3), 2759–2766;
Published: 1 September 2006
(This article belongs to the Special Issue Pathogenesis of tumor progression in breast and prostate cancer)

Uridine phosphorylase (UPase) is an enzyme that converts the pyrimidine nucleoside uridine into uracil. Upon availability of ribose-1-phosphate, UPase can also catalyze the formation of nucleosides from uracil as well as from 5-fluorouracil, therefore involved in fluoropyrimidine metabolism. UPase gene expression is strictly controlled at the promoter level by oncogenes, tumor suppressor genes, and cytokines. UPase activity is usually elevated in various tumor tissues, including breast cancer, compared to matched normal tissues and this induction appears to contribute to the therapeutic efficacy of fluoropyrimidines in cancer patients. In this review, we will discuss in detail the role of UPase in the activation of fluoropyrimidines and its effect on the prognosis of breast cancer patients.

Uridine Phosphorylase
Thymidine Phosphorylase
Breast Cancer
Prognostic Factor
5’-Deoxy-5- fluorouridine
Gene Expression
and Gene Knockout
Back to top